TY - JOUR
T1 - Molecular typing of cryptosporidium in Israel
AU - Grossman, Tamar
AU - Ken-Dror, Shifra
AU - Pavlotzky, Elsa
AU - Vainer, Julia
AU - Glazer, Yael
AU - Sagi, Orli
AU - Peretz, Avi
AU - Agmon, Vered
AU - Marva, Esther
AU - Valinsky, Lea
N1 - Publisher Copyright:
© 2019 Grossman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Cryptosporidium is a protozoan parasite associated with gastrointestinal illness. In immunecompromised individuals, the infection may become life-threatening. Cryptosporidiosis is a mandatory-reported disease but little was known about its prevalence and associated morbidity in Israel. Currently, laboratory diagnosis is based on microscopy or copro-antigen tests and the disease is underreported. Molecular assays, which are more sensitive and specific, are now increasingly used for identification and screening. Here, the molecular epidemiology of cryptosporidiosis is explored for the first time. Samples from 33 patients infected during an outbreak of 146 laboratory confirmed cases that occurred in Haifa and Western Galilee in 2015 were genotyped, as well as samples from 36 patients sporadically infected during 2014-2018 in different regions. The results suggest that Cryptosporidium subtypes found in Israel are more similar to those reported in the neighboring countries Jordan and Egypt than in European countries. C. hominis was the predominant species in the center and the north of Israel, implicating human-to-human transmission. C. hominis IeA11G3T3 was the most prevalent subtype contributing to morbidity.
AB - Cryptosporidium is a protozoan parasite associated with gastrointestinal illness. In immunecompromised individuals, the infection may become life-threatening. Cryptosporidiosis is a mandatory-reported disease but little was known about its prevalence and associated morbidity in Israel. Currently, laboratory diagnosis is based on microscopy or copro-antigen tests and the disease is underreported. Molecular assays, which are more sensitive and specific, are now increasingly used for identification and screening. Here, the molecular epidemiology of cryptosporidiosis is explored for the first time. Samples from 33 patients infected during an outbreak of 146 laboratory confirmed cases that occurred in Haifa and Western Galilee in 2015 were genotyped, as well as samples from 36 patients sporadically infected during 2014-2018 in different regions. The results suggest that Cryptosporidium subtypes found in Israel are more similar to those reported in the neighboring countries Jordan and Egypt than in European countries. C. hominis was the predominant species in the center and the north of Israel, implicating human-to-human transmission. C. hominis IeA11G3T3 was the most prevalent subtype contributing to morbidity.
UR - http://www.scopus.com/inward/record.url?scp=85071778181&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0219977
DO - 10.1371/journal.pone.0219977
M3 - Article
C2 - 31479457
AN - SCOPUS:85071778181
SN - 1932-6203
VL - 14
JO - PLoS ONE
JF - PLoS ONE
IS - 9
M1 - e0219977
ER -